Filing Details

Accession Number:
0001567619-19-004919
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-02-19 17:50:58
Reporting Period:
2019-02-14
Accepted Time:
2019-02-19 17:50:58
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
874716 Idexx Laboratories Inc IDXX In Vitro & In Vivo Diagnostic Substances (2835) 010393723
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1094176 Anne M Szostak One Idexx Drive
Westbrook ME 04092
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-02-14 5,906 $47.53 6,490 No 4 M Direct
Common Stock Disposition 2019-02-14 5,906 $0.00 584 No 4 G Direct
Common Stock Acquisiton 2019-02-14 5,906 $0.00 9,322 No 4 G Indirect by M. Anne Szostak Trust
Common Stock Disposition 2019-02-14 5,906 $208.96 3,416 No 4 S Indirect by M. Anne Szostak Trust
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 G Direct
No 4 G Indirect by M. Anne Szostak Trust
No 4 S Indirect by M. Anne Szostak Trust
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Non-Qualified Stock Option (right-to-buy) Disposition 2019-02-14 5,906 $0.00 5,906 $47.53
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2019-08-31 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 12,000 Indirect by 2018 Szostak IDEXX GRAT
Footnotes
  1. Represents the weighted average price of the shares sold ranging from a low of $208.8350 to a high of $209.1750 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
  2. Grant of option to buy 2,953 shares of IDEXX Laboratories, Inc. common stock that became exercisable in one annual installment on September 1, 2013 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
  3. Not applicable.